Headache Medicine Highlights from the 2026 AAN Annual Meeting - Part 1

A groundbreaking shift in migraine treatment is emerging from the 2026 AAN Annual Meeting, with a new TRPM8 antagonist—Lismatrep—showing promising results in a phase 2 trial for acute migraine relief, marking the first time a non-neural, cold-sensing receptor has been targeted for migraine therapy. Despite a technical hiccup that initially rendered the primary endpoint non-significant, patient-reported data confirmed a strong response, turning the study into a positive outcome. This breakthrough, combined with the failure of a preventive monoclonal (preminazumab) in chronic pediatric migraine but success in episodic cases, challenges the rigid 15-day diagnostic threshold and underscores the need for earlier, more aggressive treatment in youth. Meanwhile, the eMERGE trial demonstrates that a combination of meloxicam and risotriptan can effectively treat patients who’ve failed CGRP inhibitors, reinforcing the importance of personalized, multi-modal approaches. The rise of Bocunibart, a novel anti-PACAP antibody with potential CGRP-independent mechanisms, and the unexpected weight-loss effect of atogepant—dose-dependent and independent of GI side effects—further expand the therapeutic landscape, suggesting central nervous system effects beyond pain modulation. Together, these findings signal a new era of precision headache medicine, where mechanism-driven, combinatorial, and patient-specific strategies are reshaping clinical practice.